{"filings":[{"id":92689,"accession_number":"0001104659-26-042125","cik":1410428,"company_name":"XWELL, Inc.","ticker":"XWEL","form_type":"8-K/A","filed_at":"2026-04-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"XWELL board adopts annual Say-on-Pay votes following stockholder preference","event_type":"other","confidence":"high","bullets":["Board determined on April 9, 2026, to hold Say-on-Pay votes every year after stockholders expressed preference for annual frequency at Dec. 18, 2025 meeting.","Next advisory vote on frequency of Say-on-Pay votes will occur at 2031 Annual Meeting unless presented earlier.","This amendment to Form 8-K adds disclosure required by Item 5.07(d) regarding board's frequency decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92690,"accession_number":"0001104659-26-038550","cik":1410428,"company_name":"XWELL, Inc.","ticker":"XWEL","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"XWELL reports FY 2025 revenue of $29.2M, net loss $17.0M; $31.3M private placement in Feb 2026","event_type":"earnings","confidence":"high","bullets":["Revenue $29.2M: XpresSpa $18.6M, XpresCheck $8.3M, Naples Wax Center $2.3M.","Operating loss $15.7M vs $16.7M prior year; net loss attributable to XWELL $17.0M vs $16.9M.","Cost of sales down 13% YoY; G&A down 20%; total operating expenses down 10%.","Opened new wellness location at NYC Penn Station in Dec 2025; expanded in Florida.","Feb 2026 private placement raised ~$31.3M; funds to repurchase notes and redeem Series G Preferred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103721,"accession_number":"0001104659-26-023569","cik":1410428,"company_name":"XWELL, Inc.","ticker":"XWEL","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"XWELL closes $31.3M private placement of Series H preferred and warrants; repurchases $9M notes","event_type":"other_material","confidence":"high","bullets":["Aggregate gross proceeds of $31,333,000 from issuance of 31,333 Series H convertible preferred (conversion price $0.47) and warrants to purchase 66,665,957 common shares (exercise price $0.345).","Placement agent Dominari Securities received warrants to purchase up to 5,333,277 common shares with same terms.","Used $9M of proceeds to repurchase outstanding Notes and redeem all Series G preferred stock and Series Warrants from prior investors.","Filed Certificate of Elimination for Series G preferred (none outstanding) and Certificate of Designations for Series H preferred.","Private Placement closed in two tranches on Feb 27 and Mar 3, 2026; relied on Section 4(a)(2)/Reg D exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103720,"accession_number":"0001104659-26-019431","cik":1410428,"company_name":"XWELL, Inc.","ticker":"XWEL","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["1.01","3.02","5.02","5.03","8.01","9.01"],"status":"ready","headline":"XWELL raises ~$31.3M via Series H convertible preferred and warrants; repurchases $9M of existing securities","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$31.3M from sale of 31,333 Series H convertible preferred shares (convertible at $0.47/sh) and 66.7M warrants (exercise $0.345/sh, 3yr).","Uses $9M of proceeds to repurchase $5.96M notes, redeem all Series G preferred, and redeem 8.8M warrants from institutional investors.","Remaining proceeds for general corporate purposes and working capital.","Board grants 100,000 shares restricted stock to each of five directors (500,000 total), vesting 30 days after closing.","Dominari Securities LLC acted as exclusive placement agent; receives 8% fee and warrants for 8% of shares underlying securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119985,"accession_number":"0001104659-25-122574","cik":1410428,"company_name":"XWELL, Inc.","ticker":"XWEL","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"XWELL shareholders approve reverse split, share issuance; reject board classification","event_type":"other_material","confidence":"high","bullets":["Proposal 6 passed: authorizes reverse stock split at ratio 1:2 to 1:20, at Board's discretion within one year.","Proposal 7 passed: permits issuance of shares >19.99% of outstanding under Exchange Agreement for Series G preferred, warrants, notes.","Proposal 5 failed: board classification into two classes with staggered terms rejected (For: 1,789,561, Against: 721,530).","All five director nominees (Ezra Ernst, Bruce Bernstein, Robert Weinstein, Gaëlle Wizenberg, Michael Lebowitz) reelected with majority support.","Advisory say-on-pay approved with ~78% of votes cast; future frequency set at every three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119984,"accession_number":"0001104659-25-118877","cik":1410428,"company_name":"XWELL, Inc.","ticker":"XWEL","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"XWELL receives Nasdaq bid price deficiency notice; cure period through June 2026","event_type":"regulatory","confidence":"high","bullets":["Closing bid price below $1.00 for 30 consecutive business days ended Nov 28, 2025.","Compliance period of 180 days, ending June 1, 2026, to regain $1.00 minimum bid.","Must maintain $1.00 closing bid for 10 consecutive days to cure deficiency.","If not cured, may qualify for additional 180 days by meeting other listing standards.","No immediate impact on trading; stock continues on Nasdaq during cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119983,"accession_number":"0001104659-25-112604","cik":1410428,"company_name":"XWELL, Inc.","ticker":"XWEL","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"XWELL reports Q3 2025 revenue of $7.3M, net loss narrows to $0.7M","event_type":"earnings","confidence":"high","bullets":["Revenue $7.3M in Q3 2025; net loss attributable to XWELL $0.7M vs $4.8M in Q3 2024.","Cost of sales down 8%; G&A expenses down 32% from prior-year quarter.","Priority Pass partnership expanded to international airports in Middle East and Europe.","Opened off-airport wellness centers in Brandon, FL and Orlando, FL; Penn Station location set for mid-November.","After Q3, streamlined cost structure, reducing approx $2.4M in annualized staffing costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":22056000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119982,"accession_number":"0001104659-25-112475","cik":1410428,"company_name":"XWELL, Inc.","ticker":"XWEL","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"XWELL exchanges $1.55M Series G Preferred for $3.39M convertible notes; amends terms","event_type":"other_material","confidence":"high","bullets":["Exchanged $1,553,806 Stated Value of Series G Preferred Stock (including accrued dividends) for $3,387,138.80 senior secured convertible notes.","Filed Certificate of Amendment reducing Series G conversion price to $1.00 and removing requirement to maintain 200% cash reserves for conversion shares.","Added anti-dilution price-based adjustments to conversion price and provisions for accelerated conversion at lower of installment price or 80% VWAP.","Closing occurred November 10, 2025; exchange intended to modify rights of Series G Preferred holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119981,"accession_number":"0001104659-25-108548","cik":1410428,"company_name":"XWELL, Inc.","ticker":"XWEL","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"XWELL sets 2025 annual meeting for Dec 18; shareholder proposal deadline Nov 17","event_type":"other","confidence":"high","bullets":["Annual meeting date moved by more than 30 days from prior year; meeting set for Dec 18, 2025 at 10:00 am ET.","Shareholder proposals under Rule 14a-8 must be received by Nov 17, 2025.","Director nominations and other business outside Rule 14a-8 due Nov 17, 2025.","Universal proxy rule compliance notice also required by Nov 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119980,"accession_number":"0001104659-25-106407","cik":1410428,"company_name":"XWELL, Inc.","ticker":"XWEL","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["1.01","2.03","3.02","3.03","5.03","9.01"],"status":"ready","headline":"XWELL exchanges $1.55M Series G Preferred for $3.39M secured notes; warrants amended","event_type":"other_material","confidence":"high","bullets":["Exchanged $1,553,806 aggregate Stated Value of Series G Preferred Stock for $3,387,138.80 senior secured convertible notes.","Notes bear 8% interest, mature in 3 years 4 months, convertible at $1.00/share; quarterly installments start Apr 1, 2026.","Warrants exercise price reduced from $1.496/$1.7952 to $1.00; anti-dilution provisions added.","Certificate of Amendment removes cash covenant, reduces Series G conversion price to $1.00, adds anti-dilution.","Company must hold stockholder meeting by Dec 31, 2025 to approve share issuances exceeding 19.99% limit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119979,"accession_number":"0001104659-25-098042","cik":1410428,"company_name":"XWELL, Inc.","ticker":"XWEL","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"XWELL cancels 2025 annual meeting, withdraws proxy proposals; to reschedule later","event_type":"other_material","confidence":"high","bullets":["Annual meeting originally set for Sept 16, 2025, was adjourned to Oct 10, 2025.","Company cancels meeting and withdraws all proposals from Aug 8 proxy statement.","New meeting will be rescheduled; a new proxy statement will be filed with SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136554,"accession_number":"0001104659-25-090545","cik":1410428,"company_name":"XWELL, Inc.","ticker":"XWEL","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"XWELL adjourns 2025 annual meeting to Oct 10, 2025 for more voting time","event_type":"other","confidence":"high","bullets":["Annual Meeting opened and adjourned on Sept 16, 2025 without conducting any business.","Reconvened virtually on Oct 10, 2025 at 10:00 a.m. ET at www.virtualshareholdermeeting.com/NAOV2025SM2.","Record date remains July 25, 2025; new proxy deadline is 11:59 p.m. ET on Oct 9, 2025.","All previously submitted proxies remain valid; shareholders do not need to revote unless changing their vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136553,"accession_number":"0001104659-25-078661","cik":1410428,"company_name":"XWELL, Inc.","ticker":"XWEL","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"XWELL Q2 2025 revenue $7.7M, net loss $2.3M widens YoY","event_type":"earnings","confidence":"high","bullets":["Revenue $7.7M, down from $9.3M YoY; sequential improvement from Q1 2025's $7.0M.","Operating loss $2.7M vs $1.9M YoY; net loss $2.3M vs $2.0M YoY.","Cash and equivalents $5.3M; marketable securities $2.9M; no long-term debt.","Named official wellness spa of Orlando Magic; expanded Priority Pass partnership.","CDC biosurveillance contract extended three years through March 2025 renewal."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":14712000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136552,"accession_number":"0001104659-25-075185","cik":1410428,"company_name":"XWELL, Inc.","ticker":"XWEL","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"XWELL regains Nasdaq minimum bid price compliance; delisting risk removed","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter confirming compliance with Listing Rule 5550(a)(2) as bid price closed at or above $1.00 for 16 consecutive days.","Compliance period measured from July 16, 2025 to August 6, 2025; matter now closed.","Previously notified of non-compliance on May 13, 2025; this resolution eliminates potential delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136551,"accession_number":"0001104659-25-070824","cik":1410428,"company_name":"XWELL, Inc.","ticker":"XWEL","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"XWELL amends bylaws to lower stockholder vote threshold to majority of votes cast (excluding abstentions)","event_type":"other_material","confidence":"high","bullets":["Board approved First Amendment to Third Amended and Restated Bylaws on July 24, 2025, effective same date.","For matters other than director elections, vote threshold changed from majority of voting power of shares present to majority of votes cast (excluding abstentions and broker non-votes).","Similar change applies to class votes where separate vote is required.","Directors continue to be elected by plurality of votes cast; no change to director election standard."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153742,"accession_number":"0001104659-25-051002","cik":1410428,"company_name":"XWELL, Inc.","ticker":"XWEL","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"XWELL Q1 revenue falls to $7.0M; net loss $4.7M; CDC contract extended 3 years","event_type":"earnings","confidence":"high","bullets":["Revenue $7.0M, down 19% from $8.7M YoY; net loss attributable $4.7M vs $2.5M.","Cost of sales down 6% to $5.7M; operating expenses down 11% to $4.5M; operating loss $3.2M.","Closed $4M private placement (Series G preferred + warrants) in Jan 2025; cash $3.7M, marketable securities $7.3M, no debt.","Secured 3-year extension of CDC Traveler-based Genomic Surveillance Program (TGS) in March 2025.","Plans to acquire medical spas in Orlando, Dallas, Salt Lake City; new XWELL location at NYC Penn Station mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":7023000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153741,"accession_number":"0001104659-25-050498","cik":1410428,"company_name":"XWELL, Inc.","ticker":"XWEL","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"XWELL (XWEL) receives Nasdaq minimum bid price deficiency notice; cure period to Nov 10, 2025","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified XWELL on May 13, 2025 that its common stock's closing bid price was below $1.00 for 30 consecutive business days (Mar 31 - May 12, 2025).","Company has 180 calendar days, until November 10, 2025, to regain compliance by maintaining a $1.00 closing bid for at least ten consecutive business days.","If not compliant by Nov 10, XWELL may qualify for an additional 180-day period if it meets all other Nasdaq Capital Market initial listing standards.","There can be no assurance of eligibility for an additional cure period or that Nasdaq will grant continued listing if delisting proceedings begin.","The notice has no immediate impact on listing; XWELL's common stock continues to trade on Nasdaq pending compliance with other requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153740,"accession_number":"0001104659-25-036830","cik":1410428,"company_name":"XWELL, Inc.","ticker":"XWEL","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"XWELL dismisses Marcum, engages CBIZ CPAs; cites material weaknesses","event_type":"regulatory","confidence":"high","bullets":["Dismissed Marcum LLP and engaged CBIZ CPAs as auditor for FY2025, effective April 21, 2025.","Marcum's reports for FY2024 and FY2023 were unqualified except for going-concern qualification in FY2024.","Disclosed material weaknesses in internal controls: lease accounting, entity-level monitoring, IT vendor controls, revenue process, foreign subsidiaries.","No disagreements or reportable events (other than material weaknesses) between Company and Marcum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153739,"accession_number":"0001104659-25-035179","cik":1410428,"company_name":"XWELL, Inc.","ticker":"XWEL","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"XWELL reports FY 2024 revenue $33.9M (+13% YoY), net loss narrows to $16.9M","event_type":"earnings","confidence":"high","bullets":["Revenue $33.9M (+13% YoY); gross margin rose to 26.3% from 12.2%.","Net loss attributable to XWELL narrowed to $16.9M from $27.7M in 2023.","CDC extended Traveler-based Genomic Surveillance Program for 3 years; base value $53.7M, ceiling $85.7M.","Closed $4M private placement in Jan 2025; plans to acquire medical spas in select metros in 2025.","Cash & equivalents $4.6M, marketable securities $7.3M, no long-term debt."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":7023000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153738,"accession_number":"0001104659-25-034194","cik":1410428,"company_name":"XWELL, Inc.","ticker":"XWEL","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"XWELL stockholders OK share issuance for Series G financing, boost equity plan to 3.125M; classified board fails","event_type":"other_material","confidence":"high","bullets":["Share issuance for Jan 2025 Series G Preferred and warrant financing approved (For: 1,329,306; Against: 328,079) to comply with Nasdaq listing rule.","Classified board amendment rejected (For: 1,287,324; Against: 530,101); board remains annually elected.","Equity incentive plan shares increased by 2.5M to total 3.125M shares; non-employee director annual award limit raised to $750,000.","Ratification of CBIZ CPAs P.C. as fiscal 2025 auditor approved (For: 2,918,213)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172422,"accession_number":"0001104659-25-023236","cik":1410428,"company_name":"XWELL, Inc.","ticker":"XWEL","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"XWELL plans medical spa acquisitions; $4M private placement to fund expansion by year-end 2025","event_type":"other_material","confidence":"high","bullets":["Plan to acquire select medical spas by end of 2025, leveraging a $4M private placement.","Initial focus on metropolitan areas: Orlando, Austin, and Salt Lake City.","Services will include injectables, body sculpting, laser therapies, and weight loss management.","CEO Ezra Ernst positions this as a move to create a nationwide brand for holistic self-care.","Global med spa market cited as rapidly growing; XWELL aims to blend luxury with medical expertise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172421,"accession_number":"0001104659-25-020597","cik":1410428,"company_name":"XWELL, Inc.","ticker":"XWEL","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"XWELL announces three-year CDC contract extension for Traveler-based Genomic Surveillance through 2027","event_type":"other_material","confidence":"high","bullets":["CDC extends Traveler-based Genomic Surveillance Program contract with XWELL for three additional years through 2027.","Contract renewal continues partnership between XWELL and CDC; financial terms not disclosed.","Announcement made on March 5, 2025 via press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}